Antineoplastic-dendritic polymer drug delivery system
Antineoplastic dendritic polymer conjugates which are useful drug delivery systems for carrying antineoplastic agents to malignant tumors are prepared. The antineoplastic agent is encapsulated within the dendritic polymer using an ionic charge shunt mechanism, whereby, the antineoplastic agent interacts with the anionic functional groups on the surface of the dendritic polymer allowing the antineoplastic agent to be uptaken by the dendritic polymer through an association with the functional groups of the interior of the dendritic polymer. The antineoplastic dendritic polymer conjugates may be administered intravenously, orally, parentally, subcutaneously, intraarterially or topically to an animal having a malignant tumor in an amount which is effective to inhibit growth of the malignant tumor. The antineoplastic dendritic polymer conjugates exhibit high drug efficiency, high drug carrying capacity, good water solubility, good stability on storage, and reduced toxicity.
1 . An antineoplastic dendritic polymer conjugate, comprising an antineoplastic agent selected from the group consisting of a platinum, titanium, vanadium, niobium, molybdenum, rhenium, or tin metal containing analogue compound of an antineoplastic agent encapsulated within a dendritic polymer containing anionic functional terminal groups.
2 . (canceled)
3 . The antineoplastic dendritic polymer conjugate of claim 1 , wherein said antineoplastic agent is a compound having a tetravalent platinum atom bonded to the nitrogen atom of two amine ligands, which may be the same or different, the amine ligands being in cis confirmation in respect to each other.
4 . The antineoplastic dendritic polymer conjugate of claim 1 , wherein said antineoplastic agent is cisplatin, carboplatin, oxalipatin, teraplatin, [platinium]platinum-DACH, ormaplatin, titanocene dichloride, vanadocene dichloride, niobocene dichloride, molybdenocene dichloride, rhenocene dichloride, diorganotin dihalides or other metal containing antineoplastic agents.
5 . The antineoplastic dendritic polymer conjugate of claim 1 or 4 , wherein the antineoplastic agent is a platin-based analogue.
6 . The antineoplastic dendritic polymer conjugate of claim 5 , wherein said platin-based analogue is cisplatin or carboplatin.
7 . The antineoplastic dendritic polymer conjugate of claim 1 , wherein the antineoplastic agent can be conjugated to the surface of the dendritic polymer with a linker.
8 . The antineoplastic dendritic polymer conjugate of claim 5 , wherein the molar ratio of said platin-based analogue to dendritic polymer is from about 100:1 to about 1:1.
9 . The antineoplastic dendritic polymer conjugate of claim 8 , wherein the molar ratio of said platin-based analogue to dendrimer is about 35:1.
10 . (canceled)
11 . The antineoplastic dendritic polymer of claim 1 , wherein said dendritic polymer contains [caboxylic]carboxylic acid terminal groups.
12 . The antineoplastic dendritic polymer conjugate of claim 1 , 4 , 6 , 7 or 11 , wherein said dendritic polymer is a dendrimer.
13 . The antineoplastic dendritic polymer conjugate of claim 1 or 11 , wherein said dendrimer is a poly(amidoamine) or poly(propyleneimine) dendrimer.
14 . The antineoplastic dendritic polymer conjugate of claim 13 , wherein the dendrimer is a poly(amidoamine) dendrimer of a generation from 3.5 to 7.5.
15 . A method for preparing an antineoplastic dendritic polymer conjugate of claim 1 , comprising:
providing a dendritic polymer having functional groups which are accessible to an antineoplastic agent capable of interacting with said functional groups in a suitable solvent;
contacting the dendritic polymer with an antineoplastic agent in a suitable solvent under conditions sufficient to cause the antineoplastic agent to associate with the dendritic polymer; and
allowing the antineoplastic agent sufficient time to be encapsulated within the dendritic polymer.
16 . The method of claim 15 , wherein the antineoplastic agent is a platin-based analogue.
17 . The method of claim 16 , wherein the platin-based analogue is cisplatin or carboplatin.
18 . The method of any one of claims 15 - 17 , wherein the dendritic polymer is a dendrimer.
19 . The method of claim 18 , wherein the dendritic polymer is a poly(amidoamine) or a poly(propyleneimine) dendrimer.
20 . (canceled)
21 . The method of claims 15 , wherein the anionic functional terminal groups are carboxylic acids.
22 . The method of claim 15 , wherein the dendritic polymer is dissolved in water and is contacted with an antineoplastic agent dissolved in water.
23 . The method of claim 15 , wherein the antineoplastic agent is a platin-based analogue with a molar ratio to the dendritic polymer in the conjugate from about 100:1 to 1:1.
24 . The method of claims 23 , wherein the molar ratio of the platin-based analogue to the dendritic polymer in the conjugate is from about 35:1.
25 . The method of claim 23 or 24 , wherein the platin-based analogue is cisplatin or carboplatin.